Aptose Biosciences Inc. APS.TO
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · TSX · Canada · aptose.com
Aptose Biosciences Inc. is a Toronto-based clinical-stage biotechnology company developing oral kinase inhibitors for hematologic malignancies. Its lead asset tuspetinib (HM43239) has completed Phase 1/2 clinical trials targeting acute myeloid leukemia (AML) and higher-risk myelodysplastic syndromes (MDS).
Key ratios
ReturnOnAssets TTM -1.53
ReturnOnAssets 2025 -1.53
ReturnOnAssets 2024 -1.42
ReturnOnAssets 2023 -1.02
ReturnOnEquity TTM -6.94
ReturnOnEquity 2023 -2.94
Recent news
Aptose Biosciences Announces Completion of Acquisition by Hanmi Pharmaceutical
2026-06-30 · GlobeNewswire
Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2026 EHA Congress in Oral Presentation
2026-06-15 · Aptose Biosciences IR
Aptose Biosciences Announces Update on Anticipated Timing of Closing of the Plan of Arrangement with Hanmi Pharmaceutical
2026-05-29 · Aptose Biosciences IR
Aptose Reports First Quarter 2026 Results
2026-05-13 · GlobeNewswire